SIOX News and Press, Sio Gene Therapies Inc. From 02/11/22

Sio Gene Therapies press release (NASDAQ:SIOX): Q3 GAAP EPS of -$0.35 misses by $0.12. Cash and cash equivalents of $81.9M as of December 31, 2021  Shares -2.50% PM. For further details see: Sio Gene Therapies GAAP EPS of -$0.35 misses by $0.12

Company prioritizing industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease $81.9 million of cash and cash equivalents as of December 31, 2021, providing exp...

NEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that it will present dat...

Gainers: Dave (NASDAQ:DAVE) +37%. Windtree Therapeutics (NASDAQ:WINT) +24%. BioRestorative Therapies (NASDAQ:BRTX) +19%. Creative Realities (NASDAQ:CREX) +19%. Biofrontera (NASDAQ:BFRI) +18%. voxeljet (NASDAQ:VJET) +18%. Immunic (NASDAQ:IMUX) +18%. Digihost Technology (NASDAQ:DGHI) +17%. Hype...

Gainers: Biofrontera (NASDAQ:BFRI) +14%. Synaptogenix (NASDAQ:SNPX) +11%. IceCure Medical (NASDAQ:ICCM) +10%. Immunic (NASDAQ:IMUX) +10%. Oncternal Therapeutics (NASDAQ:ONCT) +10%. Losers: Sio Gene Therapies (NASDAQ:SIOX) -19%. Anavex Life Sciences (NASDAQ:A...

SIOX made stellar progress in 2021. Moreover, it is resuming an important gene therapy program in Parkinson's disease. Yet the market is essentially assigning the company's programs and FDA drug designations zero value. I believe this sets up a very favorable risk/reward situa...

–   Data from AXO-AAV-GM1 Phase 1/2 study demonstrated consistent dose-dependent biomarker improvement including normalization of beta-galactosidase activity in serum and GM1 ganglioside in CSF –   Granted Fast Track Designation for both AXO-AAV-GM1...

- Completed three successful GMP campaigns using suspension-based manufacturing process - All batches achieved target titers and have successfully completed fill and finish - Qualified Person (QP) certification of at least one batch of clinical trial material on-track for Q4 2...

The U.S. FDA has granted a Fast Track Designation to Sio Gene Therapies' (NASDAQ:SIOX) AXO-AAV-GM2, an investigational gene therapy for the treatment of early infantile, late infantile, and juvenile-onset Tay-Sachs and Sandhoff disease. Shares up more than 5% premarket. Th...

-   Designation complements previously granted Rare Pediatric Disease and Orphan Drug designations -   Enrollment ongoing in the registration-enabling trial of AXO-AAV-GM2 in Tay-Sachs/Sandhoff diseases NEW YORK and DURHAM, N.C., Nov. 01, 2021 (GLOBE NEWSWI...